 |
MorphoSys AG
MOR
|
1.75 |
- |
2.43 % |
$ 254 M |
Germany |
 |
Amphastar Pharmaceuticals
AMPH
|
1.73 |
$ 21.87 |
2.15 % |
$ 1.02 B |
USA |
 |
I-Mab
IMAB
|
94.1 |
- |
- |
$ 866 M |
China |
 |
Aeglea BioTherapeutics
AGLE
|
489 |
- |
- |
$ 1.01 B |
USA |
 |
Midatech Pharma plc
MTP
|
137 |
- |
-18.52 % |
$ 27.3 M |
Britain |
 |
Alexion Pharmaceuticals, Inc.
ALXN
|
5.53 |
- |
- |
$ 40.3 B |
USA |
 |
Aptorum Group Limited
APM
|
105 |
$ 0.9 |
- |
$ 6.62 M |
China |
 |
Genfit SA
GNFT
|
1.96 K |
- |
2.54 % |
$ 160 B |
France |
 |
ACADIA Pharmaceuticals
ACAD
|
3.33 |
$ 22.28 |
1.46 % |
$ 3.69 B |
USA |
 |
EyeGate Pharmaceuticals, Inc.
EYEG
|
2.39 K |
- |
-1.52 % |
$ 24.7 M |
USA |
 |
Advaxis
ADXS
|
144 |
- |
-9.65 % |
$ 45.9 M |
USA |
 |
AIkido Pharma
AIKI
|
0.935 |
- |
1.93 % |
$ 17.4 M |
USA |
 |
Ampio Pharmaceuticals
AMPE
|
106 |
- |
-11.43 % |
$ 502 K |
USA |
 |
Институт стволовых клеток человека
ISKJ
|
2.61 |
- |
- |
- |
Russia |
 |
Aeterna Zentaris
AEZS
|
7.87 |
- |
5.93 % |
$ 314 M |
Canada |
 |
Applied Therapeutics
APLT
|
54.1 |
- |
- |
$ 8.42 M |
USA |
 |
Aptinyx
APTX
|
204 |
- |
-39.0 % |
$ 4.57 M |
USA |
 |
AgeX Therapeutics
AGE
|
0.099 |
- |
-10.17 % |
$ 12.2 K |
USA |
 |
Aravive
ARAV
|
6.61 |
- |
-13.39 % |
$ 1.45 M |
USA |
 |
Aridis Pharmaceuticals
ARDS
|
1.34 |
- |
17.91 % |
$ 11.1 M |
USA |
 |
BioNTech SE
BNTX
|
35.7 |
$ 105.26 |
-0.19 % |
$ 27.2 B |
Germany |
 |
Applied Genetic Technologies Corporation
AGTC
|
65.5 |
- |
- |
$ 26.5 M |
USA |
 |
Aquestive Therapeutics
AQST
|
10.5 |
$ 4.1 |
0.37 % |
$ 438 M |
USA |
 |
Arcutis Biotherapeutics
ARQT
|
9.15 |
$ 23.98 |
3.07 % |
$ 3.05 B |
USA |
 |
Ayala Pharmaceuticals
AYLA
|
11.2 |
- |
- |
$ 7.46 M |
Israel |
 |
Autolus Therapeutics plc
AUTL
|
4.27 |
$ 1.47 |
1.74 % |
$ 391 M |
Britain |
 |
AstraZeneca PLC
AZN
|
2.17 |
- |
- |
$ 96.9 B |
Britain |
 |
Can-Fite BioPharma Ltd.
CANF
|
759 |
$ 2.98 |
2.41 % |
$ 4.91 M |
Israel |
 |
BioDelivery Sciences International
BDSI
|
1.85 |
- |
-4.8 % |
$ 255 M |
USA |
 |
BeiGene, Ltd.
BGNE
|
66.4 |
- |
0.49 % |
$ 251 B |
Cayman-islands |
 |
CureVac N.V.
CVAC
|
281 |
- |
- |
$ 867 M |
Germany |
 |
bluebird bio
BLUE
|
2.27 |
- |
- |
$ 546 M |
USA |
 |
Cardiff Oncology
CRDF
|
196 |
$ 1.72 |
- |
$ 115 M |
USA |
 |
BioXcel Therapeutics
BTAI
|
24 |
$ 1.1 |
3.76 % |
$ 13.4 M |
USA |
 |
Cabaletta Bio
CABA
|
50.3 M |
$ 2.97 |
0.68 % |
$ 298 M |
USA |
 |
Cara Therapeutics
CARA
|
2.58 |
- |
-3.03 % |
$ 260 M |
USA |
 |
CASI Pharmaceuticals
CASI
|
36.1 |
- |
- |
$ 35.4 M |
USA |
 |
CymaBay Therapeutics
CBAY
|
110 |
- |
- |
$ 3.45 B |
USA |